Your session is about to expire
← Back to Search
Haploidentical Transplant for Severe Aplastic Anemia
Study Summary
This trial is for patients with Severe Aplastic Anemia who will receive a haploidentical transplantation (from a family member that is not fully matched). The primary objective is to assess the rate of engraftment at 30 days and overall survival (OS) and event free survival (EFS) at 1 year.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have a matching family or unrelated donor for a cell transplant.You had a life-threatening reaction (like anaphylaxis) to ATG in the past, which means you cannot use it again.My potential donor is ready and can donate stem cells.I am 18 years old or older.I do not have an ongoing infection that isn't getting better with treatment.I have been diagnosed with dyskeratosis congenita.My bone marrow test shows changes linked to early or actual MDS.You are not currently breastfeeding a baby.I am 21 years old or younger.I have been diagnosed with Fanconi anemia, confirmed by specific testing.I have had a stem cell transplant from a donor.I have been diagnosed with severe aplastic anemia or a single blood cell deficiency, confirmed by specific blood and bone marrow tests.I have not received Alemtuzumab or ATG in the last 2 weeks.I have severe aplastic anemia and did not respond well to or relapsed after immunosuppressive therapy.I have had a solid organ transplant.My related donors have been checked and do not have telomere disease.I have antibodies against a donor organ.I have a family member who is at least a half match for a transplant.I am not pregnant or breastfeeding.I have had cancer before, but it was either treated over 5 years ago, was a basal cell carcinoma that was removed, or was a treated cervical carcinoma in situ.I have been diagnosed with myelodysplastic syndrome.I have a family member who is a partial match for a donation.
- Group 1: Haploidentical HCT
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any harmful side effects associated with Total Lymphoid Irradiation (TLI)?
"Total Lymphoid Irradiation (TLI) has some evidence backing its safety, but as this is only a Phase 2 trial, there is no data yet to support efficacy. Therefore, it received a score of 2."
Are new participants being accepted into this research project at present?
"Yes, this study is still looking for volunteers. According to the clinicaltrials.gov website, the trial was initially posted on 1/21/2021 and last updated on 8/26/2022."
How many total participants are needed for this research project?
"The information available on clinicaltrials.gov verifies that this study is currently looking for 21 individuals to fill the 1 remaining locations. This particular trial was first posted on January 21st, 2021 and was most recently updated on August 26th, 2022."
Why was this clinical trial designed in the first place?
"The primary goal of this trial, as measured over the course of 1 year, is engraftment. Additionally, we will track secondary outcomes like immune reconstitution (defined as the order and magnitude of leukocyte subtype recovery), graft rejection (the rate of secondary rejections post-transplant), and viral reactivation (occurrence of CMV, EBV or adenovirus post-transplant)."
What is the research precedent for Total Lymphoid Irradiation (TLI)?
"As of now, there are over one-thousand studies investigating Total Lymphoid Irradiation (TLI). Out of those 183 live clinical trials are in the final stage. Most of the research surrounding TLI is based in Philadelphia, but this treatment is being studied at 30287 locations worldwide."
What are some benefits of Total Lymphoid Irradiation (TLI)?
"Total Lymphoid Irradiation (TLI) is a medical procedure that has shown efficacy in the treatment of lung cancers. Additionally, this therapy can be used to treat conditions such as mobilization of hematopoietic stem cells therapy, immunosuppressive treatment, and multiple sclerosis."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger